Literature DB >> 9142134

Th1 and Th2 CD4+ cells in the pathogenesis of allergic diseases.

D T Umetsu1, R H DeKruyff.   

Abstract

Our understanding of the molecular and genetic etiologies of allergic disorders, which affect 20%-30% of the general population, has greatly improved over the past several years. Previously, research focused on examination of immediate hypersensitivity reactions, initiated by the cross-linking of IgE molecules on the surface of mast cells/basophils, resulting in the release of a host of mediators, which cause symptoms typified by acute anaphylaxis. Although there has been substantial progress in understanding the molecular biology of mast cell and basophil activation and of the regulation of IgE synthesis, recent studies have shifted attention to the cellular and molecular mechanisms that cause a broader allergic inflammatory response and underlie the more chronic and severe symptoms of allergy and asthma. In this report, we will review a substantial body of recent experimental work that has provided the basis for our new understanding of the allergic inflammatory response and the pathogenesis of allergic diseases. We will describe the recent progress in defining the immunological basis for allergic disease, and how subsets of helper CD4+ T cells secreting a specific array of cytokines (Th2 cytokines) regulate/cause allergic inflammation. We will review the cell biology of Th2 cells, the role of Th2 cells in allergic disease, and biological, genetic, and therapeutic mechanisms that influence the differentiation of CD4+ T cells and enhance or suppress cytokine synthesis in Th2 cells. These mechanisms control the expression of allergic diseases, which occur in some but not all individuals following environmental exposure to allergens.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9142134     DOI: 10.3181/00379727-215-44109

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  16 in total

1.  Kinetics of GATA-3 gene expression in early polarizing and committed human T cells.

Authors:  E Lantelme; S Mantovani; B Palermo; R Campanelli; F Sallusto; C Giachino
Journal:  Immunology       Date:  2001-02       Impact factor: 7.397

Review 2.  Evolving paradigms in the pathogenesis of IBD.

Authors:  Lloyd Mayer
Journal:  J Gastroenterol       Date:  2009-12-04       Impact factor: 7.527

Review 3.  The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy.

Authors:  V K Singh; S Mehrotra; S S Agarwal
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 4.  Innate and adaptive immunity in inflammatory bowel disease.

Authors:  Britta Siegmund; Martin Zeitz
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

Review 5.  Inhibition of histone deacetylases in inflammatory bowel diseases.

Authors:  Rainer Glauben; Britta Siegmund
Journal:  Mol Med       Date:  2011-02-22       Impact factor: 6.354

6.  Regulation of TH1- and TH2-type cytokine expression and action in atopic asthmatic sensitized airway smooth muscle.

Authors:  H Hakonarson; N Maskeri; C Carter; M M Grunstein
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

Review 7.  Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin.

Authors:  Sanjoy Roychowdhury; Craig K Svensson
Journal:  AAPS J       Date:  2005-12-09       Impact factor: 4.009

8.  Autocrine interaction between IL-5 and IL-1beta mediates altered responsiveness of atopic asthmatic sensitized airway smooth muscle.

Authors:  H Hakonarson; N Maskeri; C Carter; S Chuang; M M Grunstein
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

9.  AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity.

Authors:  Nicholas W Lukacs; Aaron Berlin; Dominique Schols; Renato T Skerlj; Gary J Bridger
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

10.  Needleless intranasal administration of HVJ-E containing allergen attenuates experimental allergic rhinitis.

Authors:  Eri Yasuoka; Kazuo Oshima; Katsuto Tamai; Takeshi Kubo; Yasufumi Kaneda
Journal:  J Mol Med (Berl)       Date:  2006-10-28       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.